Grünenthal issued notice to the European Commission (EC) and the European Medicines Agency (EMA) to withdraw Zurampic® (lesinurad)1 and Duzallo® (lesinurad and allopurinol, currently not marketed)2 for the treatment of chronic hyperuricaemia in adults with gout, who have not achieved target serum uric acid levels with an adequate dose of a Xanthine Oxidase Inhibitor (XOI) alone, from the market in Europe. Zurampic and Duzallo will not be marketed in Latin America.

Thomas Schöffmann

Geschäftsführer Grünenthal Ges.m.b.H. Österreich

Grünenthal Ges.m.b.H.

Brunn am Gebirge


Telefon: 02236 / 379550

E-Mail: thomas.schö